Evvy Closes $40M to Expand Fertility Diagnostics

The big picture: Evvy, a New York-based company, has closed a $40 million Series B round led by Catalio Capital Management. The funding will push its vaginal microbiome platform, built on a dataset from over 100,000 patients, into fertility diagnostics. Evvy aims to replace diagnostic uncertainty in women’s health with data-driven insights.

Why it matters:

• Addressing a gap: Women’s health has historically been under-researched, leading to ‘unexplained’ diagnoses for conditions like infertility and recurring infections.
• Data-driven approach: Evvy’s platform, EvvyAI, leverages a large dataset of vaginal microbiome information to identify biomarkers and provide targeted treatments.
• Market expansion: Moving into fertility diagnostics positions Evvy in a rapidly growing segment of the women’s health market, attracting significant investment.

How it works:

• Metagenomic sequencing: Evvy’s at-home test uses advanced sequencing to identify over 700 bacteria and fungi, offering a more comprehensive view than standard tests.
• EvvyAI platform: The company’s machine-learning engine processes patient data to discover biomarkers, leading to more accurate diagnoses and personalized treatment plans.
• Clinical integration: Results are routed through licensed clinicians who can prescribe targeted treatments, demonstrated to reduce recurrence rates for conditions like bacterial vaginosis.

The catch: The women’s health market is seeing increased investment, but competition is intensifying, with larger virtual-care platforms like Maven Clinic and Midi Health raising substantial rounds. While Evvy emphasizes its unique diagnostic layer, its ability to out-execute these broader, well-funded platforms as it expands beyond its niche into fertility diagnostics remains to be seen. The challenge will be scaling its specialized data-driven approach effectively within a broader, more competitive landscape.